Savara Inc.
SVRA
$0.08
Change (1 day)
$5.70
Year High
$2.82
Year Low
Categories
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Earnings for Savara Inc. (SVRA)
Earnings in 2023 (TTM): $-54,698,000
According to Savara Inc.'s latest financial reports the company's current earnings (TTM) are $-54,698,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Savara Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-54,698,000 | $-54,698,000 |
| 2022 | $-38,150,000 | $-38,946,000 |
| 2021 | $-43,014,000 | $-45,296,000 |
| 2020 | $-49,615,000 | $-51,097,000 |
| 2019 | $-78,173,000 | $-105,025,000 |
| 2018 | $-70,027,000 | $-61,516,000 |
| 2017 | $-33,431,000 | $-29,797,000 |
| 2016 | $-11,280,000 | $-10,923,000 |
| 2015 | $-39,842,000 | $-39,842,000 |
| 2014 | $-28,702,000 | $-28,702,000 |
| 2013 | $-21,480,285 | $-21,480,285 |
| 2012 | $-15,559,489 | $-15,559,489 |
| 2011 | $-13,259,931 | $-13,260,000 |
| 2010 | $-8,450,922 | $-8,450,922 |
| 2009 | $-11,325,058 | $-11,325,058 |
| 2008 | $-26,647,493 | $-26,647,493 |
| 2007 | $-22,142,040 | $-22,142,040 |
| 2006 | $29.33 M | $-29,331,773 |
| 2005 | $-24,782,646 | $-24,782,646 |
| 2004 | $-2,332,077 | $-6,701,048 |
| 2003 | $-2,332,077 | $-2,332,077 |
| 2002 | $-2,053,303 | $-2,105,727 |
| 2001 | $-16,358,791 | $-16,339,120 |
| 2000 | $ | $-3,701,084 |